Literature DB >> 33574795

Genetic and Epigenetic Causes of Pituitary Adenomas.

Mengqi Chang1, Chengxian Yang1, Xinjie Bao1, Renzhi Wang1.   

Abstract

Pituitary adenomas (PAs) can be classified as non-secreting adenomas, somatotroph adenomas, corticotroph adenomas, lactotroph adenomas, and thyrotroph adenomas. Substantial advances have been made in our knowledge of the pathobiology of PAs. To obtain a comprehensive understanding of the molecular biological characteristics of different types of PAs, we reviewed the important advances that have been made involving genetic and epigenetic variation, comprising genetic mutations, chromosome number variations, DNA methylation, microRNA regulation, and transcription factor regulation. Classical tumor predisposition syndromes include multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4) syndromes, Carney complex, and X-LAG syndromes. PAs have also been described in association with succinate dehydrogenase-related familial PA, neurofibromatosis type 1, and von Hippel-Lindau, DICER1, and Lynch syndromes. Patients with aryl hydrocarbon receptor-interacting protein (AIP) mutations often present with pituitary gigantism, either in familial or sporadic adenomas. In contrast, guanine nucleotide-binding protein G(s) subunit alpha (GNAS) and G protein-coupled receptor 101 (GPR101) mutations can lead to excess growth hormone. Moreover, the deubiquitinase gene USP8, USP48, and BRAF mutations are associated with adrenocorticotropic hormone production. In this review, we describe the genetic and epigenetic landscape of PAs and summarize novel insights into the regulation of pituitary tumorigenesis.
Copyright © 2021 Chang, Yang, Bao and Wang.

Entities:  

Keywords:  Cushing’s disease; acromegaly; molecular markers; non-secreting adenomas; pituitary adenomas

Year:  2021        PMID: 33574795      PMCID: PMC7870789          DOI: 10.3389/fendo.2020.596554

Source DB:  PubMed          Journal:  Front Endocrinol (Lausanne)        ISSN: 1664-2392            Impact factor:   5.555


  156 in total

1.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

Authors:  Quinn T Ostrom; Haley Gittleman; Peter Liao; Chaturia Rouse; Yanwen Chen; Jacqueline Dowling; Yingli Wolinsky; Carol Kruchko; Jill Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

Review 2.  Multiple endocrine neoplasia type 1 (MEN1).

Authors:  Rajesh V Thakker
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2010-06       Impact factor: 4.690

Review 3.  Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas.

Authors:  Anat Ben-Shlomo; Ning-Ai Liu; Shlomo Melmed
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

4.  Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.

Authors:  Sanne E Franck; Federico Gatto; Aart Jan van der Lely; Joseph A M J L Janssen; Alof H G Dallenga; A Paul Nagtegaal; Leo J Hofland; Sebastian J C M M Neggers
Journal:  Neuroendocrinology       Date:  2016-07-25       Impact factor: 4.914

5.  Cloning of human ENC-1 and evaluation of its expression and regulation in nervous system tumors.

Authors:  M C Hernandez; P J Andres-Barquin; I Holt; M A Israel
Journal:  Exp Cell Res       Date:  1998-08-01       Impact factor: 3.905

6.  Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas.

Authors:  Zhi Rong Qian; Sylvia L Asa; Haruhiko Siomi; Mikiko C Siomi; Katsuhiko Yoshimoto; Shozo Yamada; Elaine Lu Wang; Md Mustafizur Rahman; Hiroshi Inoue; Mitsuo Itakura; Eiji Kudo; Toshiaki Sano
Journal:  Mod Pathol       Date:  2009-01-09       Impact factor: 7.842

Review 7.  Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma.

Authors:  Yunli Zhou; Xun Zhang; Anne Klibanski
Journal:  Mol Cell Endocrinol       Date:  2013-09-11       Impact factor: 4.102

8.  Decreased expression of SFRP2 promotes development of the pituitary corticotroph adenoma by upregulating Wnt signaling.

Authors:  Jie Ren; Fangfang Jian; Hong Jiang; Yuhao Sun; Sijian Pan; Changwei Gu; Xiao Chen; Weiqing Wang; Guang Ning; Liuguan Bian; Qingfang Sun
Journal:  Int J Oncol       Date:  2018-04-03       Impact factor: 5.650

9.  The incidence of Cushing's disease: a nationwide Swedish study.

Authors:  Oskar Ragnarsson; Daniel S Olsson; Dimitrios Chantzichristos; Eleni Papakokkinou; Per Dahlqvist; Elin Segerstedt; Tommy Olsson; Maria Petersson; Katarina Berinder; Sophie Bensing; Charlotte Höybye; Britt Edén Engström; Pia Burman; Lorenza Bonelli; Cecilia Follin; David Petranek; Eva Marie Erfurth; Jeanette Wahlberg; Bertil Ekman; Anna-Karin Åkerman; Erik Schwarcz; Ing-Liss Bryngelsson; Gudmundur Johannsson
Journal:  Pituitary       Date:  2019-04       Impact factor: 4.107

10.  Succinate dehydrogenase deficiency is rare in pituitary adenomas.

Authors:  Anthony J Gill; Christopher W Toon; Adele Clarkson; Loretta Sioson; Angela Chou; Ingrid Winship; Bruce G Robinson; Diana E Benn; Roderick J Clifton-Bligh; Trisha Dwight
Journal:  Am J Surg Pathol       Date:  2014-04       Impact factor: 6.394

View more
  6 in total

1.  The Genomic Landscape of Corticotroph Tumors: From Silent Adenomas to ACTH-Secreting Carcinomas.

Authors:  Sergio Andonegui-Elguera; Gloria Silva-Román; Eduardo Peña-Martínez; Keiko Taniguchi-Ponciano; Sandra Vela-Patiño; Ilan Remba-Shapiro; Erick Gómez-Apo; Ana-Laura Espinosa-de-Los-Monteros; Lesly A Portocarrero-Ortiz; Gerardo Guinto; Sergio Moreno-Jimenez; Laura Chavez-Macias; Renata Saucedo; Lourdes Basurto-Acevedo; Blas Lopez-Felix; Carolina Gonzalez-Torres; Javier Gaytan-Cervantes; Jorge T Ayala-Sumuano; Andres Burak-Leipuner; Daniel Marrero-Rodríguez; Moisés Mercado
Journal:  Int J Mol Sci       Date:  2022-04-27       Impact factor: 6.208

2.  Methylome Analysis in Nonfunctioning and GH-Secreting Pituitary Adenomas.

Authors:  Giuseppe Giuffrida; Valeria D'Argenio; Francesco Ferraù; Vito Alessandro Lasorsa; Francesca Polito; Federica Aliquò; Marta Ragonese; Oana Ruxandra Cotta; Ylenia Alessi; Rosaria Oteri; Federica Di Maggio; Alessio Asmundo; Petronilla Daniela Romeo; Federica Spagnolo; Lucio Pastore; Filippo Flavio Angileri; Mario Capasso; Salvatore Cannavò; M'Hammed Aguennouz
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-30       Impact factor: 5.555

Review 3.  Architects of Pituitary Tumour Growth.

Authors:  Maria Eugenia Sabatino; Ezequiel Grondona; Ana Lucía De Paul
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-28       Impact factor: 6.055

4.  Ubiquitin Specific Protease USP48 Destabilizes NF-κB/p65 in Retinal Pigment Epithelium Cells.

Authors:  Serena Mirra; Laura Sánchez-Bellver; Carmela Casale; Alessandra Pescatore; Gemma Marfany
Journal:  Int J Mol Sci       Date:  2022-08-26       Impact factor: 6.208

5.  A Pituitary Carcinoma Patient With Cerebrospinal Fluid Dissemination Showing a Good Response to Temozolomide Combined With Whole-Brain and Spinal Cord Radiotherapy: A Case Report and Literature Review.

Authors:  Peng Du; Xuefan Wu; Kun Lv; Ji Xiong; Daoying Geng
Journal:  Front Oncol       Date:  2022-07-12       Impact factor: 5.738

6.  A Common Variant in the CDK8 Gene Is Associated with Sporadic Pituitary Adenomas in the Portuguese Population: A Case-Control Study.

Authors:  Leonor M Gaspar; Catarina I Gonçalves; Fernando Fonseca; Davide Carvalho; Luísa Cortez; Ana Palha; Inês F Barros; Ema Nobre; João S Duarte; Cláudia Amaral; Maria J Bugalho; Olinda Marques; Bernardo D Pereira; Manuel C Lemos
Journal:  Int J Mol Sci       Date:  2022-10-04       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.